Bristol-Myers Squibb revealed that its new drug for stroke currently being developed in association with Pfizer has shown to be better than warfarin according to the results from their latest trial.
Lead investigator for the trial, Dr Christopher Granger revealed that the drug, known as apixaban, performed "significantly better" than warfarin in the Phase III trial. According to the trial, apixaban reduced the risk of stroke by more than 21 percent when compared with warfarin.
The researchers went on to add that those who took apixaban had fewer stroke and major bleeding events and were also less likely to die compared to warfarin. The drug also reduced the risk of bleeding by 31 percent.
"There is an enormous unmet need in terms of treatment of patients at risk for stroke associated with atrial fibrillation. Only about half of patients who should be treated are being treated. The disparity exists because warfarin treatment has several limitations", the researchers said in a statement.